MicroRNA's and prediction of recovery from heartfailure

Published: 02-03-2010 Last updated: 04-05-2024

If certain combinations of micro RNA's that are predictive for recovery exist, they can be improtant for prognostic reasons and play a role in postponing device implantation. It may also help in choosing the right pharmaceutic regiment.

Ethical review	Approved WMO
Status	Pending
Health condition type	Heart failures
Study type	Observational invasive

Summary

ID

NL-OMON32850

Source ToetsingOnline

Brief title mRNA-HF

Condition

• Heart failures

Synonym decompensatio cordis, heartfailure

Research involving Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Heartfailure, Micro RNA, Prediction, Recovery

Outcome measures

Primary outcome

Upregulation of certain mRNA's in patients with (de novo) systolic heartfailure>

Changes in this upregulation in recovery?

Value in predicting recovery?

Secondary outcome

Study description

Background summary

A new way to study gene expression in heartfailure is to look at micro-RNA's. It's possible that there are certain combinations of micro RNA's that are helpfull in the predicion of recovery.

We know that there are certain mRNA's that are upregulated in patients with heartfailure and that there is clustering of several mRNA's in certain patient groups. The exact meaning in recovery /deterioration is yet unknown.

Study objective

If certain combinations of micro RNA's that are predictive for recovery exist, they can be improtant for prognostic reasons and play a role in postponing device implantation. It may also help in choosing the right pharmaceutic regiment.

Study design

Prospective study of all patients with first presentation systolic heartfailure. (In- and outpatient clinic)

Study burden and risks

No extra risk or burden for the patient.

Contacts

Public Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam NL **Scientific** Academisch Medisch Centrum

Meibergdreef 9 1105 AZ Amsterdam NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Systolic heartfailure

Exclusion criteria

EF > 40%

Study design

Design

Study type: Observational invasive		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Basic science	

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-10-2009
Enrollment:	80
Туре:	Anticipated

Ethics review

Approved WMO	
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

ССМО

ID NL30055.018.09